Trial Profile

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in Participants With Early or Acute Hematogenous PJI Requiring or Not Requiring DAIR After TKA, or Requiring Long-term Antibiotic Therapy

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Levofloxacin (Primary) ; Minocycline (Primary) ; Rifampicin (Primary) ; Rifaquizinone (Primary) ; Vancomycin (Primary) ; Vancomycin (Primary)
Indications Bone and joint infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
Focus Adverse reactions; Proof of concept
Sponsors TenNor Therapeutics

08 Sep 2025 Number of treatment arms are increased from 3 to 4 by the addition of Experimental: Expansion group arm, with 10 additional planned patients.
08 Sep 2025 Planned number of patients changed from 23 to 33.
08 Apr 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com